AstraZeneca

STUDY REPORT SUMMARY

ASTRAZENECA PHARMACEUTICALS

FINISHED PRODUCT: Crestor
ACTIVE INGREDIENT: Rosuvastatin

Study No: NIS-CFR-CRE-2010/1
SCAVANCE : Evaluation of compliance with management of Acute Coronary Syndrome on discharge from Cardiac Intensive Care.

Developmental Phase: Not applicable
Study Completion Date: 12-AUG-2010
Date of Report: 26-10-2010

OBJECTIVES:

The primary objective was to measure, using an electronic system ("intelligent blister pack®"), the duration of treatment and number of treatment intake per day over 3 months with statin and oral antiplatelet therapy following an inaugural acute coronary syndrome.

The main secondary objectives were to :

- analyse the duration of treatment and number of treatment intake per day at 1 month and 2 months with a statin and a platelet aggregation inhibitor, using an electronic system ("intelligent blister pack®")
- describe global compliance with the entire prescription over 6 months
- determine the factors influencing compliance with treatment on discharge from CIC.

METHODS: This was a national, multicentre, longitudinal, prospective, cohort follow-up, observational study

Sixty CIC units were recruited to participate in the study, with the expected participation of a total of 60 to 100 cardiologists. Patients meeting the selection criteria of the study were consecutively included by cardiologists of the participating CIC units, until the constitution of a 1,000 patients cohort.

RESULTS:

Between April and August 2010, 15 CIC cardiologists recruited 32 adult patients admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the cardiologist considers that Crestor® - rosuvastatin was the most appropriate statin for management in hospital, in combination with a platelet aggregation inhibitor (Plavix® - clopidogrel).

In August 2010, considering the low patient inclusion rate (32 patients recruited so far whereas study objective was 1000 patients), the study was ended prematurely. No analysis was conducted afterwards.